This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brey, R L Articles by Shoenfeld, Y Search for Related Content PubMed PubMed Citation Articles by Brey, R L Articles by Shoenfeld, Y Social Bookmarking                         What's this?

Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002

Department of Medicine, Division of Neurology, University of Texas Health Science Center - San Antonio, Texas, USA, brey{at}uthscsa.edu

J Chapman

Department of Neurology, Chaim Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel

S R Levine

Stroke Program, Department of Neurology, The Mount Sinai School of Medicine, New York, USA

G Ruiz-Irastorza

Service of Internal Medicine, Hospital de Cruces, Department of Medicine, University of the Basque Country, 48903-Bizkaia, Spain

R HWM Derksen

Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands

M Khamashta

Lupus Unit, The Rayne Institute, St Thomas’ Hospital, London, UK

Y Shoenfeld

Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel

Ischaemic stroke is the only neurological manifestation accepted as a clinical diagnostic criterion for the antiphospholipidsyndrome (APS). This association is reasonably well established in patients first diagnosed with APS but is less clear in randomly selected stroke patients who test positive on one occasion for antiphospholipid antibodies and who have no other evidence of systemic autoimmune disease. We propose a grading system that posits stroke to be definitely, likely or possibly associated with antiphospholipid antibodies (aPL). Further, there are limited prospective data to determine appropriatetreatment. There is controversy as to whether the presence of aPL even increases risk of a recurrent stroke or other thromboembolic event, although data point to persistent medium-high titre aCL and/or LA as risk factors for recurrence. In the absence of data to guide clinicians on the best treatment, we cannot make strong recommendations as to optimal therapy, nor can we propose clear consensus treatment guidelines.

Key Words: anticoagulanttherapy • antiphospholipidantibodies • antiphospholipidsyndrome • cerebrovascular disorders • lupus anticoagulant • stroke

Lupus, Vol. 12, No. 7, 508-513 (2003)
DOI: 10.1191/0961203303lu390oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Kaul, D. Erkan, L. Sammaritano, and M. D Lockshin Assessment of the 2006 revised antiphospholipid syndrome classification criteria Ann Rheum Dis, July 1, 2007; 66(7): 927 - 930. [Abstract] [Full Text] [PDF]

				T Tarr, G Lakos, H P Bhattoa, Y Shoenfeld, G Szegedi, and E Kiss Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients Lupus, January 1, 2007; 16(1): 39 - 45. [Abstract] [PDF]

				M L Bertolaccini and M A Khamashta Laboratory diagnosis and management challenges in the antiphospholipid syndrome Lupus, March 1, 2006; 15(3): 172 - 178. [Abstract] [PDF]

				W. Lim, M. A. Crowther, and J. W. Eikelboom Management of Antiphospholipid Antibody Syndrome: A Systematic Review JAMA, March 1, 2006; 295(9): 1050 - 1057. [Abstract] [Full Text] [PDF]

				G. Ruiz-Irastorza and M. A. Khamashta Stroke and antiphospholipid syndrome: the treatment debate Rheumatology, August 1, 2005; 44(8): 971 - 974. [Abstract] [Full Text] [PDF]

				J Alijotas-Reig and A Cistero-Bahima Letter to the Editor Lupus, July 1, 2004; 13(7): 554 - 554. [PDF]

				H. J. Fullerton and E. von Scheven Back to school on APS: Rethinking the risk of recurrent stroke in children Neurology, January 27, 2004; 62(2): 172 - 173. [Full Text] [PDF]